Qili Qiangxin Capsule Combined With Sacubitril/Valsartan for HFrEF: A Systematic Review and Meta-Analysis

Background: Heart failure with reduced ejection fraction (HFrEF) is a complex, chronic disease and is among the top causes of morbidity and mortality. Angiotensin receptor-neprilysin inhibitor drugs represented by sacubitril/valsartan are the key drugs for the treatment of HFrEF in western medicine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiang, Qian, Wang, Mengxi, Ding, Yuhan, Fan, Manlu, Tong, Huaqin, Chen, Jiandong, Yu, Peng, Shen, Le, Chen, Xiaohu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014182/
https://www.ncbi.nlm.nih.gov/pubmed/35444529
http://dx.doi.org/10.3389/fphar.2022.832782

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014182/
https://www.ncbi.nlm.nih.gov/pubmed/35444529
http://dx.doi.org/10.3389/fphar.2022.832782

Ejemplares similares